Literature DB >> 33654176

A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.

Toshiki Ochi1,2, Masaki Maruta3, Kazushi Tanimoto3, Fumitake Kondo3, Toshihiro Yamamoto4, Mie Kurata4,5, Hiroshi Fujiwara3,6, Junya Masumoto4,5, Katsuto Takenaka3, Masaki Yasukawa7,8.   

Abstract

Cancer immunotherapy using T cells redirected with chimeric antigen receptor (CAR) has shown a lot of promise. We have established a single-chain antibody (scFv) generation system in which scFv library-expressing CAR-T cells can be screened appropriately based on their antitumor functions. A variable region library containing the variable and J regions of the human immunoglobulin light or heavy chain was fused with the variable region of a heavy or light chain encoded by an existing tumor-specific antibody to generate a new scFv library. Then, scFv library-expressing CAR-T cells were generated and stimulated with target cells to concentrate the antigen-specific population. Using this system, target-specific recognition of CAR-T cells appeared to be finely tuned by selecting a new variable region. Importantly, we have demonstrated that the newly optimized scFv-expressing CAR-T cells had better proliferation capacity and durable phenotypes, enabling superior reactivity against advanced tumors in vivo in comparison with the original CAR-T cells. Therefore, the optimization of an scFv is needed to maximize the in vivo antitumor functions of CAR-T cells. This system may allow us to adjust an immunological synapse formed by an scFv expressed by CAR-T cells and a target antigen, representing an ideal form of CAR-T-cell immunotherapy.

Entities:  

Year:  2021        PMID: 33654176      PMCID: PMC7925539          DOI: 10.1038/s42003-021-01791-1

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  50 in total

1.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

Authors:  Melinda Mata; Claudia Gerken; Phuong Nguyen; Giedre Krenciute; David M Spencer; Stephen Gottschalk
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

3.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.

Authors:  Martin Hülsmeyer; Patrick Chames; Roman C Hillig; Robyn L Stanfield; Gerhard Held; Pierre G Coulie; Claudia Alings; Gabriele Wille; Wolfram Saenger; Barbara Uchanska-Ziegler; Hennie R Hoogenboom; Andreas Ziegler
Journal:  J Biol Chem       Date:  2004-11-10       Impact factor: 5.157

5.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

Review 6.  Chimeric antigen receptor T-cell therapies for lymphoma.

Authors:  Jennifer N Brudno; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

7.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

Authors:  Xiaojun Liu; Shuguang Jiang; Chongyun Fang; Shiyu Yang; Devvora Olalere; Edward C Pequignot; Alexandria P Cogdill; Na Li; Melissa Ramones; Brian Granda; Li Zhou; Andreas Loew; Regina M Young; Carl H June; Yangbing Zhao
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

8.  Tuning the Antigen Density Requirement for CAR T-cell Activity.

Authors:  Robbie G Majzner; Skyler P Rietberg; Elena Sotillo; Rui Dong; Vipul T Vachharajani; Louai Labanieh; June H Myklebust; Meena Kadapakkam; Evan W Weber; Aidan M Tousley; Rebecca M Richards; Sabine Heitzeneder; Sang M Nguyen; Volker Wiebking; Johanna Theruvath; Rachel C Lynn; Peng Xu; Alexander R Dunn; Ronald D Vale; Crystal L Mackall
Journal:  Cancer Discov       Date:  2020-03-19       Impact factor: 39.397

9.  Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

Authors:  Sara Ghorashian; Anne Marijn Kramer; Shimobi Onuoha; Gary Wright; Jack Bartram; Rachel Richardson; Sarah J Albon; Joan Casanovas-Company; Fernanda Castro; Bilyana Popova; Krystle Villanueva; Jenny Yeung; Winston Vetharoy; Aleks Guvenel; Patrycja A Wawrzyniecka; Leila Mekkaoui; Gordon Weng-Kit Cheung; Danielle Pinner; Jan Chu; Giovanna Lucchini; Juliana Silva; Oana Ciocarlie; Arina Lazareva; Sarah Inglott; Kimberly C Gilmour; Gulrukh Ahsan; Mathieu Ferrari; Somayya Manzoor; Kim Champion; Tony Brooks; Andre Lopes; Allan Hackshaw; Farzin Farzaneh; Robert Chiesa; Kanchan Rao; Denise Bonney; Sujith Samarasinghe; Nicholas Goulden; Ajay Vora; Paul Veys; Rachael Hough; Robert Wynn; Martin A Pule; Persis J Amrolia
Journal:  Nat Med       Date:  2019-09-02       Impact factor: 53.440

10.  Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.

Authors:  Masaki Maruta; Toshiki Ochi; Kazushi Tanimoto; Hiroaki Asai; Takashi Saitou; Hiroshi Fujiwara; Takeshi Imamura; Katsuto Takenaka; Masaki Yasukawa
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

View more
  1 in total

Review 1.  Development of CAR T Cell Therapy in Children-A Comprehensive Overview.

Authors:  Michael Boettcher; Alexander Joechner; Ziduo Li; Sile Fiona Yang; Patrick Schlegel
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.